Translational toxicology of sex specific PFNA clearance in rat and human

  • Christoph HetheyEmail author
  • Hans Mielke
  • Ursula Gundert-Remy
Letter to the Editor, News and Views

Kim et al. proposed a physiologically based toxicokinetic (PBTK) model for perfluorononanoic acid (PFNA) and perfluorodecanoic acid (PFDA) (Kim et al. 2019). In the absence of human-specific data they extrapolated findings from rats to humans. This being possible is one of the great advantages of PBTK modeling. While on the right path, they may want to amend their reasoning to avoid logical fallacies and arrive at sound conclusions.

The model proposed by Kim et al. explicitly rules out tubular secretion for PFNA and PFDA (Kim et al. 2019). We challenged this assumption to avoid potentially wrong conclusions in human risk assessment (Hethey et al. 2019). The response (Choi et al. 2019) did not convince us, but highlighted the key difference to our calculation: where we used an array of experimentally determined values for the glomerular filtration rate (GFR), they focus on an assumed value.

Clearly, given values for renal plasma clearance (CLren) and unbound fraction (Fr), deductions...



  1. Breljak D, Ljubojević M, Hagos Y, Micek V, Eror D, Madunić I, Brzica H, Karaica D, Radović N, Kraus O et al (2016) Distribution of organic anion transporters NaDC3 and OAT1-3 along the human nephron. Am J Physiol Renal Physiol 311:F227–F238CrossRefGoogle Scholar
  2. Calafat AM, Wong L-Y, Kuklenyik Z, Reidy JA, Needham LL (2007) Polyfluoroalkyl chemicals in the U.S. population: data from the National Health and Nutrition Examination Survey (NHANES) 2003–2004 and comparisons with NHANES 1999–2000. Environ Health Perspect 115:1596–1602CrossRefGoogle Scholar
  3. Choi GW, Kim JH, Lee YB, Cho HY (2019) Response to Hethey et al., 2019 letter to the editor in archives of toxicology. Arch Toxicol 93:3033–3035CrossRefGoogle Scholar
  4. Davies B, Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm. Res. 10:1093–1095CrossRefGoogle Scholar
  5. Harada K, Inoue K, Morikawa A, Yoshinaga T, Saito N, Koizumi A (2005) Renal clearance of perfluorooctane sulfonate and perfluorooctanoate in humans and their species-specific excretion. Environ Res 99:253–261CrossRefGoogle Scholar
  6. Hethey C, Mielke H, Gundert-Remy U (2019) Comment on ‘Exploring sex differences in human health risk assessment for PFNA and PFDA using a PBPK model, Arch Toxicol 93:311–330’. Arch Toxicol 93:1769–1770CrossRefGoogle Scholar
  7. Kim S-J, Choi E-J, Choi G-W, Lee Y-B, Cho H-Y (2019) Exploring sex differences in human health risk assessment for PFNA and PFDA using a PBPK model. Arch Toxicol 93:311–330CrossRefGoogle Scholar
  8. Kudo N, Katakura M, Sato Y, Kawashima Y (2002) Sex hormone-regulated renal transport of perfluorooctanoic acid. Chem Biol Interact 139:301–316CrossRefGoogle Scholar
  9. Loccisano AE, Campbell JL, Butenhoff JL, Andersen ME, Clewell HJ (2012) Comparison and evaluation of pharmacokinetics of PFOA and PFOS in the adult rat using a physiologically based pharmacokinetic model. Reprod Toxicol 33:452–467CrossRefGoogle Scholar
  10. Olsen GW, Burris JM, Ehresman DJ, Froehlich JW, Seacat AM, Butenhoff JL, Zobel LR (2007) Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. Environ Health Perspect 115:1298–1305CrossRefGoogle Scholar
  11. Pestel S, Krzykalla V, Weckesser G (2007) Measurement of glomerular filtration rate in the conscious rat. J Pharmacol Toxicol Methods 56:277–289CrossRefGoogle Scholar
  12. Sabolic I, Breljak D, Ljubojevi M, Brzica H (2011) Are mice, rats, and rabbits good models for physiological, pharmacological and toxicological studies in humans? Period Biol 113:10Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Bundesinstitut für RisikobewertungBerlinGermany

Personalised recommendations